The Comparison of Olanzapine and Risperidone Treatment in Male Schizophrenic Patients using Positive and Negative Syndromes Scale (PANSS)

Authors

  • Endah Tri Lestari Universitas Sumatera Utara, Fakultas Kedokteran, Psychiatry, Medan, Sumatera Utara
  • Elmeida Effendy Universitas Sumatera Utara, Fakultas Kedokteran, Psychiatry, Medan, Sumatera Utara
  • Mustafa Mahmud Amin Universitas Sumatera Utara, Fakultas Kedokteran, Psychiatry, Medan, Sumatera Utara
  • Bahagia Bahagia Loebis Universitas Sumatera Utara, Fakultas Kedokteran, Psychiatry, Medan, Sumatera Utara

DOI:

https://doi.org/10.3889/oamjms.2018.153

Keywords:

Risperidone, Olanzapine, PANSS, Male schizophrenic patients, Acute phase of treatment

Abstract

INTRODUCTION: The most common method to compare olanzapine and risperidone is by calculating the score of positive and negative syndromes scale (PANSS). However, there were some conflicting results mentioned from previous studies.

AIM: This study aimed to compare the treatment of olanzapine and risperidone using PANSS, limited to only male patients receiving inpatient treatment to obtain more significant results.

METHODS: The subjects of this study were male schizophrenic patients in the acute phase of treatment (N = 68) who were hospitalised at the Mental Hospital Prof. Dr M. Ildrem, Indonesia. These participants were divided into two groups and treated with different atypical antipsychotics (olanzapine, 20 mg/day [n = 34]; risperidone, 6 mg/day [n = 34]). The scores of PANSS from both groups were collected from pre-test and post-test after 6 -week treatment.

RESULTS: The improvement of the schizophrenia symptoms measured by PANSS after 6 weeks showed significant differences in the scores of PANSS between the male patient groups treated with olanzapine and risperidone (p-value < 0.001).

CONCLUSION: The group of olanzapine shows a higher improvement of the scores of PANSS than that the group of risperidone.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Tamminga CA. Schizophrenia and Other Psychotic Disorders :Introduction and Overview. In: Sadock BJ, Sadock VA, Ruiz P, Editor. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2017:1433.

Kane JM, Leucht S, Carpenter D, Docherty JP. Expert Consensus Guideline Series. Optimizing pharmacologic treatment of psychotic disorders. Medication Selection, Dosing, And Dose Equivalence. J Clin Psychiatry. 2003; 64(Suppl12):21-51.

Canive JM, Miller GA, Irwin JG, et al. Efficacy of Olanzapine and Risperidone in Schizophrenia: A Randomized Double-Blind Crossover Design. Psychopharmacology Bulletin. 2006; 39(1):105-16. PMid:17065975

Ingole S, Belorkar NR, Waradkar P, Shrivastava M. Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients. Indian J Physiol Pharmacol. 2009; 53 (1):47–54. PMid:19810576

Rahiminejad F, Akhondzadeh S. Pharmacotreatment of Schizophrenia: Ploypharmacy Approaches. Acta Medica Iranica. 2010; 48(4): 203-8. PMid:21279929

Gottlieb J, Fan X, Goff DC. Rating scales in schizophrenia. In: Baer L, Blais MA, Editor. Handbook of clinical rating scales and assessment inpsychiatry and mental health. New York: Humana Press, 2010: 209-19.

Conley RR, Mahmoud R. A Randomized Double-Blind Study of Risperidone and Olanzapine in the Treatment of Schizophrenia or Schizoaffective Disorder. Am J Psychiatry. 2001; 158:765–74. https://doi.org/10.1176/appi.ajp.158.5.765 PMid:11329400

Shah SK, Ojha SP, Koirala NR, Sharma VD, Yengkokpam B. A comparison of efficacy of risperidone and olanzapine in schizophrenia patients. Journal of College of Medical Sciences-Nepal. 2011; (3):29-35.

Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997; 17:407–18. https://doi.org/10.1097/00004714-199710000-00010 PMid:9315992

Kumar PN, Anish PK, Rajmohan V. Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia. Indian Journal of Psychiatry. 2016; 58(3):311-6. https://doi.org/10.4103/0019-5545.192016 PMid:28066010 PMCid:PMC5100124

Departemen Kesehatan Republik Indonesia. Pedoman Penggolongan dan Diagnosis Gangguan Jiwa di Indonesia III (PPDGJ-III). Jakarta, 1993.

Dahlan MS. Membaca dan Menelaah Jurnal Uji Klinis. Jakarta: Salemba Medika, 2010: 65-74

Sastroasmoro S, Ismail S. Dasar-Dasar Metodologi Penelitian Klinis. Edisi Ketiga. Jakarta: Sagung Seto. 2008: 202-19.

Stahl SM. Essential Psychopharmacology Prescriber's guide. Risperidone. 5th ed. New York: Cambridge University Press, 2015: 593-602

Sadock BJ, Sadock VA, Sussman N. Anticholinergics and Amantadine. In: Kaplan&Sadock's Pocket Handbook Of Psychiatric Drug Treatment. Lippincott Williams & Wilkins, 2006: 46-52

Opler LA, Opler MG, Malaspina D. Reducing guesswork in schizophrenia treatment: PANSS can target and gauge treatment, predict outcomes. Current Psychiatry. 2006; 5 (9):76-84.

Montoya A, Valladares A, Lizán L, San L, Escobar R, Paz S. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health and Quality of Life Outcomes. 2011; 9:18. https://doi.org/10.1186/1477-7525-9-18 PMid:21447155 PMCid:PMC3078838

Amir N. Pedoman Definisi PANSS (Positive and Negative Syndromes Scale). Jakarta: Fakultas Kedokteran Universitas Indonesia, 2008: 4-24. PMid:18387033

Dahlan MS. Statistik untuk kedokteran dan kesehatan: deskriptif, bivariat dan multivariat, dilengkapi dengan menggunakan SPSS. Edisi kelima. Jakarta: Salemba Medika, 2014: 91-136.

Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL. Practice Guideline for the Treatment of Patients with Schizophrenia. 2nd ed.US: American Psychiatry Association, 2010: 52-53.

Kane JM, Stroup TS, Marder SR. Schizophrenia: Psychopharmacological Treatment. In: Sadock BJ, Sadock VA, Ruiz P, Editor. Kaplan &Sadock's Comprehensive Textbook of Psychiatry. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2017: 1548-56.

Moisan J, Grégoire JP, Chabot I. Risperidone and Olanzapine Use at a Psychiatric Hospital: Comparison of Clinical Use and Acquisition Costs. Can J Hosp Pharm. 2001; 54:278-83.

Marder SR, Davis MC. Second-Generation Antipsychotics. In: Sadock BJ, Sadock VA, Ruiz P, Eds. Kaplan & Sadock comprehensive textbook of psychiatry. Vol I. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2017:8104-229.

Miyamoto S, Merrill DB, Jarskog LF, Fleishhacker WW, Marder SR, Lieberman JA. Antipsychotic Drugs. In Tasman A, Kay J, Liebermen JA, First MB, Riba MB, editors. Psychiatry. 4th ed. John Wiley & Sons, Ltd, 2015:2088-119. https://doi.org/10.1002/9781118753378.ch104

Published

2018-04-12

How to Cite

1.
Lestari ET, Effendy E, Amin MM, Bahagia Loebis B. The Comparison of Olanzapine and Risperidone Treatment in Male Schizophrenic Patients using Positive and Negative Syndromes Scale (PANSS). Open Access Maced J Med Sci [Internet]. 2018 Apr. 12 [cited 2022 Oct. 1];6(4):638-42. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2018.153

Issue

Section

B - Clinical Sciences

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>